Compare STRIDES PHARMA SCIENCE with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs NEULAND LABS - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE NEULAND LABS STRIDES PHARMA SCIENCE/
NEULAND LABS
 
P/E (TTM) x 42.1 53.9 78.2% View Chart
P/BV x 2.0 4.1 48.3% View Chart
Dividend Yield % 0.2 0.1 278.6%  

Financials

 STRIDES PHARMA SCIENCE   NEULAND LABS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
NEULAND LABS
Mar-20
STRIDES PHARMA SCIENCE/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs1,147754 152.2%   
Low Rs642247 259.6%   
Sales per share (Unadj.) Rs317.2594.5 53.4%  
Earnings per share (Unadj.) Rs7.812.6 62.1%  
Cash flow per share (Unadj.) Rs25.137.0 67.7%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.4 55.9%  
Book value per share (Unadj.) Rs274.3553.4 49.6%  
Shares outstanding (eoy) m89.5012.83 697.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.80.8 334.9%   
Avg P/E ratio x114.039.6 287.8%  
P/CF ratio (eoy) x35.713.5 264.0%  
Price / Book Value ratio x3.30.9 360.6%  
Dividend payout %25.515.8 161.0%   
Avg Mkt Cap Rs m80,0586,421 1,246.9%   
No. of employees `0002.51.3 195.6%   
Total wages/salary Rs m4,3411,236 351.3%   
Avg. sales/employee Rs Th11,325.85,949.4 190.4%   
Avg. wages/employee Rs Th1,731.4963.8 179.6%   
Avg. net profit/employee Rs Th280.1126.4 221.5%   
INCOME DATA
Net Sales Rs m28,3947,627 372.3%  
Other income Rs m94139 2,421.1%   
Total revenues Rs m29,3347,666 382.7%   
Gross profit Rs m3,9651,019 389.2%  
Depreciation Rs m1,540313 492.5%   
Interest Rs m1,962216 909.7%   
Profit before tax Rs m1,403529 265.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97367 26.5%   
Profit after tax Rs m702162 433.2%  
Gross profit margin %14.013.4 104.5%  
Effective tax rate %6.969.4 10.0%   
Net profit margin %2.52.1 116.4%  
BALANCE SHEET DATA
Current assets Rs m24,8365,152 482.1%   
Current liabilities Rs m18,9933,576 531.1%   
Net working cap to sales %20.620.7 99.6%  
Current ratio x1.31.4 90.8%  
Inventory Days Days71105 67.5%  
Debtors Days Days11391 124.8%  
Net fixed assets Rs m34,2893,969 864.0%   
Share capital Rs m895129 693.8%   
"Free" reserves Rs m23,6516,971 339.3%   
Net worth Rs m24,5467,100 345.7%   
Long term debt Rs m15,513774 2,005.1%   
Total assets Rs m65,43712,310 531.6%  
Interest coverage x1.73.5 49.7%   
Debt to equity ratio x0.60.1 579.9%  
Sales to assets ratio x0.40.6 70.0%   
Return on assets %4.13.1 132.7%  
Return on equity %2.92.3 125.3%  
Return on capital %6.99.5 72.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6975,187 302.6%   
Fx outflow Rs m7351,593 46.2%   
Net fx Rs m14,9623,594 416.3%   
CASH FLOW
From Operations Rs m1,871573 326.2%  
From Investments Rs m5,826-487 -1,196.8%  
From Financial Activity Rs m-10,157-55 18,534.5%  
Net Cashflow Rs m-2,61533 -8,021.1%  

Share Holding

Indian Promoters % 27.7 36.3 76.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 63.7 59.3%  
FIIs % 8.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 63.7 40.6%  
Shareholders   56,241 12,705 442.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  SANOFI INDIA  FULFORD INDIA  ORCHID PHARMA  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 12, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - GSK PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS